Agenovir is now part of Vir Biotechnology, a San Francisco-based company dedicated to transforming the care of people with or at risk of serious infectious diseases.

About Agenovir

Agenovir, a Vir Biotechnology company, is a leader in the research and development of a novel class of human therapeutics to address diseases associated with, or caused by, latent or persistent viral reservoirs. The individuals affected by these diseases number in the millions, and treatment options are extremely limited.

Using its deep virology expertise and targeted genome editing technologies, including CRISPR/Cas9, Agenovir’s mission is to develop innovative treatments that disrupt or eliminate pathogenic viral genomes, bringing hope to patients who suffer from devastating, persistent viral infection.

Guide RNA
Target Viral DNA
Cas9 Protein

CRISPR/Cas9 Complex

Diseases Associated with Viral Reservoirs

Agenovir is developing therapies to target and disrupt viral DNA. By interfering at the level of DNA, it may be possible to treat and eliminate latent viruses and persistent viral reservoirs for which there are no current treatments.


Human Papillomavirus


Hepatitis B


Epstein-Barr Virus




Herpes Simplex Virus


Varicella Zoster Virus

Novel Nuclease Technology

Agenovir is using state-of-the-art nucleases, including CRISPR/Cas9, to target viral DNA for disruption. By disrupting intracellular viral DNA, it may be possible to treat and eliminate persistent viral reservoirs.

Agenovir’s CRISPR/Cas9 complex includes:
  • The Cas9 protein, which act like a pair of molecular scissors to knockout viral DNA
  • Guide RNA that directs the Cas9 protein to a specific viral DNA sequence

Recent News and Insights

Learn More

Targeted viral genome editing